Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2022.
Key highlights from this period include:
FDA accepted NDA filing for Sofpironium Bromide as sufficiently complete for a substantive review
FDA confirmed that a mid-cycle review of the NDA is planned for 1Q 2023
Independent market research project completed by Triangle Insights confirms significant revenue opportunity for Sofpironium Bromide and positive feedback from key physician, payer (insurance) and patient stakeholders, who were surveyed on a blinded basis
Successfully raised $5.96M via a placement to institutional shareholder Antares Capital and Shareholder Purchase Plan to existing holders
Successful Phase 1b/2 clinical study for BTX 1702 in rosacea completed
Cash position of $8.72 million at quarter end, with pivotal Sofpironium Bromide mid-cycle review meeting due this quarter
Botanix will be attending the JP Morgan Healthcare Conference in San Francisco this week. The conference attracts more than 50,000 attendees from around the world, bringing together global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
As part of the conference, Botanix will be discussing the significant commercial potential of Sofpironium Bromide and sharing some of the independent market research recently completed by Triangle Insights.
With the formal filing of the Sofpironium Bromide NDA now accepted by FDA and a standard review period confirmed, we are pleased to report that the mid-cycle review remains on track for this quarter.
Botanix is pleased to share an analyst report published by Euroz Hartleys following this week’s announcement that our Company has received formal written communication from the FDA, confirming that our New Drug Application (NDA) for Sofpironium Bromide is suitable for substantive review, and that no issues have been identified.
Analyst Seth Lizee classified the Company as a ‘Speculative Buy, $0.27 Price Target’, and commented on this achievement:
“Overall, we view this is as yet another milestone met, bringing BOT one step closer to potential FDA approval, and in time commercialisation.”
https://botanixpharma.com/wp-content/uploads/BOT-WEBSITE-SPP-Open.png7361104Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2022-11-08 23:00:412023-03-13 21:15:27SPP Now Open
Botanix (ASX:BOT) has today lifted its trading halt, sharing news that it has secured a commitment of A$5.0million from a highly respected institutional investor, Antares Capital. The Company will also offer a limited Share Purchase Plan (SPP) for eligible AU and NZ shareholders to raise up to A$3 million.
Quarterly Activities Report and 4C Quarterly Cash Flow Report
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2022.
Key highlights from this period include:
Click here to read today’s ASX release
JP Morgan Healthcare Conference Presentation
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix will be attending the JP Morgan Healthcare Conference in San Francisco this week. The conference attracts more than 50,000 attendees from around the world, bringing together global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
As part of the conference, Botanix will be discussing the significant commercial potential of Sofpironium Bromide and sharing some of the independent market research recently completed by Triangle Insights.
With the formal filing of the Sofpironium Bromide NDA now accepted by FDA and a standard review period confirmed, we are pleased to report that the mid-cycle review remains on track for this quarter.
Click here to view the presentation.
Research Report by Euroz Hartleys – 8 December 2022
/in Featured, Latest News, News /by Haley ChartresBotanix is pleased to share an analyst report published by Euroz Hartleys following this week’s announcement that our Company has received formal written communication from the FDA, confirming that our New Drug Application (NDA) for Sofpironium Bromide is suitable for substantive review, and that no issues have been identified.
Analyst Seth Lizee classified the Company as a ‘Speculative Buy, $0.27 Price Target’, and commented on this achievement:
“Overall, we view this is as yet another milestone met, bringing BOT one step closer to potential FDA approval, and in time commercialisation.”
Read the full report.
SPP Now Open
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix’s recently announced Share Purchase Plan (SPP) to raise up to A$3 million is now open for eligible AU/NZ shareholders.
The SPP opens today, 9 November 2022 and will remain open until 8:00pm AEDT on Wednesday, 23 November 2022 (unless extended or withdrawn).
As the SPP is only open for two weeks, eligible shareholders are encouraged to apply for new shares as soon as possible.
Click here to read today’s ASX release.
A$5 million strategic Placement + Share Purchase Plan
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) has today lifted its trading halt, sharing news that it has secured a commitment of A$5.0million from a highly respected institutional investor, Antares Capital. The Company will also offer a limited Share Purchase Plan (SPP) for eligible AU and NZ shareholders to raise up to A$3 million.
Click here to read today’s ASX release.
Significant R&D Tax Incentive Refund
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix has today announced it has received a Research and Development (R&D) Tax Incentive Refund of A$3,669,439 for the 2021/2022 financial year.
Click here to read today’s ASX release.